In this context, AL001 (Latozinemab) is a recombinant human anti‐sortilin (SORT1) monoclonal IgG1 that is currently under development for the treatment of FTD‐GRN patients and C9orf72‐associated ALS. The gene discussed is SORT1; the disease is amyotrophic lateral sclerosis.